Advertisement


Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, which will be the future of lung cancer immunotherapy.



Related Videos

Skin Cancer

Howard Kaufman, MD, on Merkel Cell Carcinoma: Treatment Update

Howard Kaufman, MD, of Rutgers Cancer Institute of New Jersey, discusses a subgroup analysis of efficacy results on avelumab in chemotherapy-refractory metastatic Merkel cell carcinom...

Solid Tumors

Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherap...

Issues in Oncology

Lawrence Fong, MD, on Novel T-Cell Checkpoint Combinations

Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.

Issues in Oncology

Elizabeth Ann Mittendorf, MD, PhD, on ASCO-SITC Meeting Highlights: Expert Perspective

Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these present...

Solid Tumors

Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.

Advertisement

Advertisement



Advertisement